Reference: “Curcumin for the treatment of major depression: A randomized, double-blind, placebo controlled study,” LoPresti AL, Maes M, et al, J Affect Disord 2014 Jun 11; 167C: 368-375. (Address: School of Psychology and Exercise Science, Murdoch University, Perth, Western Australia 6150, Australia. a.lopresti@murdoch.edu.au).
Summary: In a randomized, double-blind, placebo controlled study involving 56 patients with major depressive disorder (MDD), curcumin was found to have beneficial effects. Each individual was given 500 mg curcumin or placebo, twice daily, for 8 weeks. From baseline to week 4, both curcumin and placebo were associated with improvements in the primary measures for MDD. However, from weeks 4 to 8, curcumin was significantly more effective than placebo in improving several mood-related symptoms. Greater efficacy from curcumin treatment was identified in a subgroup of individuals with atypical depression. The authors conclude that “there is significant evidence of the beneficial effects of curcumin on MDD patients. Investigations with larger sample sizes, over-extended treatment periods and with varying dosages are required.”